Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | FGFR3 - TACC3 |
Therapy | BO-264 |
Indication/Tumor Type | urinary bladder cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR3 - TACC3 | urinary bladder cancer | sensitive | BO-264 | Preclinical - Cell culture | Actionable | In a preclinical study, BO-264 treatment inhibited Erk1/2 phosphorylation, induced mitotic arrest, and reduced viability of a urinary bladder cancer cell line harboring FGFR3-TACC3 in culture (PMID: 32217742). | 32217742 |
PubMed Id | Reference Title | Details |
---|---|---|
(32217742) | A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate. | Full reference... |